News
TransCellular Therapeutics in the News
July, 2022: TCT partners with the Barth Syndrome Foundation. eml-pusa01.app.blackbaud.net/intv2/j/646C6F1B-6D02-49AE-A04E-86660216C2F0/r/646C6F1B-6D02-49AE-A04E-86660216C2F0_11d618f2-4070-44c5-84a3-9fa97863666e/l/1927B3CA-0114-4803-929D-43C11A5EEF9B/c
May, 2021: Dr. Michael Chin awarded an NIH R61 grant to develop rTERTs for commercialization. reporter.nih.gov/search/sJ3zDOhZ9ES4UykSxPZO1g/project-details/10405485#similar-Projects
August, 2016: Dr. Michael Chin awarded an NIH R01 grant to study the mechanisms of action of rTERTs in a mouse model of Barth Syndrome. https://projectreporter.nih.gov/project_info_description.cfm?aid=9174015&icde=31215117&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC
April, 2016: Dr. Michael Chin awarded an ITHS/Primate Center Ignition Award to test rTERTs in non-human primates. https://www.iths.org/blog/news/three-uw-investigators-awarded-ithsprimate-center-ignition-awards/
February, 2016: TransCellular Therapeutics receives notice of expected small business grant funding from the National Institutes of Health
July, 2015: Dr. Michael Chin awarded a grant from University of Washington CoMotion Innovation Fund for "Tafazzin enzyme replacement therapy." http://comotion.uw.edu/news/comotion-announces-2015-innovation-fund-awardees
April, 2015: Dr. Michael Chin awarded a grant from the Barth Syndrome Foundation to study "Enzyme replacement therapy in heart failure associated with tafazzin deficiency." https://www.barthsyndrome.org/science--medicine/research-grant-program/grants-awarded/Enzyme%20replacement%20therapy%20in%20heart%20failure%20associated%20with%20tafazzin%20deficiency
March, 2015: Dr. Michael Chin founds TransCellular Therapeutics, Inc.
July, 2014: Dr. Michael Chin awarded a grant from the Barth Syndrome Foundation to study "Tafazzin enzyme replacement therapy in a mouse model of Barth Syndrome." https://www.barthsyndrome.org/science--medicine/research-grant-program/grants-awarded/tafazzin-enzyme-replacement-therapy-in-a-mouse-model-of-Barth-syndrome
May, 2013: Dr. Michael Chin awarded a grant from the Barth Syndrome Foundation to study "Tafazzin enzyme replacement therapy for heart muscle in Barth Syndrome." https://www.barthsyndrome.org/science--medicine/research-grant-program/grants-awarded/tafazzin-enzyme-replacement-therapy-for-heart-muscle-in-barth-syndrome
May, 2021: Dr. Michael Chin awarded an NIH R61 grant to develop rTERTs for commercialization. reporter.nih.gov/search/sJ3zDOhZ9ES4UykSxPZO1g/project-details/10405485#similar-Projects
August, 2016: Dr. Michael Chin awarded an NIH R01 grant to study the mechanisms of action of rTERTs in a mouse model of Barth Syndrome. https://projectreporter.nih.gov/project_info_description.cfm?aid=9174015&icde=31215117&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC
April, 2016: Dr. Michael Chin awarded an ITHS/Primate Center Ignition Award to test rTERTs in non-human primates. https://www.iths.org/blog/news/three-uw-investigators-awarded-ithsprimate-center-ignition-awards/
February, 2016: TransCellular Therapeutics receives notice of expected small business grant funding from the National Institutes of Health
July, 2015: Dr. Michael Chin awarded a grant from University of Washington CoMotion Innovation Fund for "Tafazzin enzyme replacement therapy." http://comotion.uw.edu/news/comotion-announces-2015-innovation-fund-awardees
April, 2015: Dr. Michael Chin awarded a grant from the Barth Syndrome Foundation to study "Enzyme replacement therapy in heart failure associated with tafazzin deficiency." https://www.barthsyndrome.org/science--medicine/research-grant-program/grants-awarded/Enzyme%20replacement%20therapy%20in%20heart%20failure%20associated%20with%20tafazzin%20deficiency
March, 2015: Dr. Michael Chin founds TransCellular Therapeutics, Inc.
July, 2014: Dr. Michael Chin awarded a grant from the Barth Syndrome Foundation to study "Tafazzin enzyme replacement therapy in a mouse model of Barth Syndrome." https://www.barthsyndrome.org/science--medicine/research-grant-program/grants-awarded/tafazzin-enzyme-replacement-therapy-in-a-mouse-model-of-Barth-syndrome
May, 2013: Dr. Michael Chin awarded a grant from the Barth Syndrome Foundation to study "Tafazzin enzyme replacement therapy for heart muscle in Barth Syndrome." https://www.barthsyndrome.org/science--medicine/research-grant-program/grants-awarded/tafazzin-enzyme-replacement-therapy-for-heart-muscle-in-barth-syndrome